Vimta Labs in FY26: Strong Margins, New Biologics Bet, and a Steady Demand Backdrop

FY26 total income was INR 4,163 million, EBITDA INR 1,489 million (35.8 percent margin), PBT INR 1,040 million, and PAT INR 775 million (18.6 percent margin). Basic EPS was INR 17.4.

Q4 FY26 total income was INR 1,120 million, EBITDA INR 421 million (37.6 percent margin), PBT INR 290 million, and PAT INR 211 million (18.9 percent margin). Basic EPS was INR 4.7.

Management stated export revenue was around 38 percent in Q4 FY26.

The company offers drug discovery and development services (pharma analytical, clinical research, preclinical research), food and agri testing, electricals and electronics testing and certification, and environment testing and consultancy services.

Management stated systems, equipment, people, infrastructure and processes are ready for biologics and peptides contract research, with projects under discussion and inquiries from Europe, India and the US. FY27 is expected to focus on execution and building credibility.

Management said EBITDA margins may see a 1 to 2 percent correction depending on input costs and manpower inflation, but they aim to broadly maintain margins and offset pressures with top-line growth.

The presentation showed total debt of INR 33.3 million and cash and cash equivalents including other bank balances of INR 650.6 million; management described the company as net debt-free.